Novo Nordisk A/S (NYSE:NVO)‘s stock had its “hold” rating reiterated by equities research analysts at Jefferies Group in a research note issued on Sunday.

A number of other equities research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Tuesday, September 6th. JPMorgan Chase & Co. lowered shares of Novo Nordisk A/S from an “overweight” rating to a “neutral” rating in a report on Friday, September 9th. Deutsche Bank AG upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Monday, September 12th. Piper Jaffray Cos. initiated coverage on shares of Novo Nordisk A/S in a report on Friday, September 23rd. They set a “neutral” rating on the stock. Finally, HSBC upgraded shares of Novo Nordisk A/S from a “reduce” rating to a “hold” rating in a report on Wednesday, August 31st. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $61.33.

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Shares of Novo Nordisk A/S (NYSE:NVO) opened at 39.58 on Friday. The firm has a market capitalization of $100.39 billion, a P/E ratio of 18.71 and a beta of 0.73. Novo Nordisk A/S has a 1-year low of $39.03 and a 1-year high of $59.00. The stock’s 50 day moving average is $44.00 and its 200 day moving average is $51.42.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jennison Associates LLC increased its position in Novo Nordisk A/S by 16.4% in the second quarter. Jennison Associates LLC now owns 17,400,801 shares of the company’s stock worth $935,815,000 after buying an additional 2,452,120 shares during the period. Loomis Sayles & Co. L P increased its position in Novo Nordisk A/S by 8.7% in the first quarter. Loomis Sayles & Co. L P now owns 11,141,752 shares of the company’s stock worth $603,772,000 after buying an additional 894,750 shares during the period. Canada Pension Plan Investment Board bought a new position in Novo Nordisk A/S during the first quarter worth approximately $26,380,000. WCM Investment Management CA increased its position in Novo Nordisk A/S by 5.4% in the second quarter. WCM Investment Management CA now owns 8,779,522 shares of the company’s stock worth $472,163,000 after buying an additional 450,232 shares during the period. Finally, State Farm Mutual Automobile Insurance Co. increased its position in Novo Nordisk A/S by 3.5% in the first quarter. State Farm Mutual Automobile Insurance Co. now owns 4,619,014 shares of the company’s stock worth $250,305,000 after buying an additional 156,820 shares during the period. 7.54% of the stock is currently owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

5 Day Chart for NYSE:NVO

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.